Status:
COMPLETED
Non-invasive Assessment to Predict Tolerance to Fluid Removal on Intermittent Kidney Replacement Therapy
Lead Sponsor:
Centre hospitalier de l'Université de Montréal (CHUM)
Collaborating Sponsors:
The Kidney Foundation of Canada
Conditions:
Acute Kidney Injury
Chronic Kidney Disease Stage 5 on Dialysis
Eligibility:
All Genders
18+ years
Brief Summary
This prospective cohort study aim to investigate the ability of multiple types of assessments including 1) the modified Venous Excess Ultrasound (VExUS) assessment, 2) non-invasive estimation of absol...
Detailed Description
Background: Fluid accumulation and intra-dialytic hypotensive events (IDHE) are independently associated with worse prognosis in patients undergoing intermittent kidney replacement therapy (IKRT), bo...
Eligibility Criteria
Inclusion
- Adult patient ≥18 year-old
- Hospitalized at the CHUM in the intensive care unit (ICU) or general ward
- Receiving or planned ≥3x/week IKRT treatments
- Planned on-line hemodiafiltration (HDF) or hemodialysis (HD) sessions with ≥1L of fluid removal per session
Exclusion
- Planned hospital discharge, death, or transition to comfort care within 48 hours according to the attending physician
- End of active care (awaiting hospital discharge)
Key Trial Info
Start Date :
March 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 17 2024
Estimated Enrollment :
93 Patients enrolled
Trial Details
Trial ID
NCT05270759
Start Date
March 1 2022
End Date
September 17 2024
Last Update
September 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Hospitalier de l'Université de Montréal
Montreal, Quebec, Canada, H2X 0C1